A Win-Win Opportunity

Over the past seven years, the Advanced Manufacturing Technology Team at Pfizer Global Technology Services has been developing transformational technologies to optimize manufacturing process performance.

Inspired by open innovation concepts, the main objective of the Intellicentic consortium is to promote a broader uptake of advanced technologies in the biopharmaceutical industry in order to accelerate regulatory awareness and acceptance that will in turn facilitate wider utilization.

Open access to these mature and proven technologies will provide significant benefits to other companies, and the pharmaceutical industry as a whole, without the need to replicate the initial investment and development efforts. A more agile and robust end-to-end biopharmaceutical supply chain will ultimately help us to better serve our patients.